10-Q: Nutriband Inc. Reports Net Loss of $1.9 Million in Q1 2024 Amid Increased R&D Spending

Nutriband Inc. reported a net loss of $1.9 million for the first quarter of 2024, driven by a significant increase in research and development expenses related to its abuse-deterrent fentanyl transdermal system.

Summary

• Nutriband Inc. reported a net loss of $1.9 million for the first quarter ended April 30, 2024, compared to a net loss of $1 million in the same period last year.
• The increased loss was primarily due to a significant rise in research and development expenses, which totaled $974,535, up from $400,430 in the prior year.
• These expenses were mainly related to the development of the company
• s lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system.','Revenue for the quarter was $408,532, down slightly from $476,932 in the first quarter of 2023.','The company completed an $8.4 million equity financing in April 2024, with $7.12 million from related parties, to fund the continued development of AVERSA Fentanyl.','As of April 30, 2024, Nutriband had cash and cash equivalents of $8.3 million and working capital of $7.3 million.'

Sentiment

Score: 4

Explanation: The sentiment is below average due to the increased net loss, high R&D expenses, and ongoing reliance on external financing. However, the recent equity financing and potential of the AVERSA Fentanyl product provide some optimism.

Positives

• The company secured $8.4 million in equity financing, strengthening its financial position.
• The credit line facility provides additional financial flexibility.
• The AVERSA Fentanyl product has the potential to address a significant need in the market for abuse-deterrent opioid products.
• The company
• s patent for its Aversa technology platform was issued in January 2022.','The acquisition of Pocono Coated Products and Active Intelligence has diversified the company's revenue streams.'

Negatives

• The company reported a larger net loss of $1.9 million compared to the previous year.
• Research and development expenses are substantial and expected to continue.
• Revenue decreased slightly compared to the same period last year.
• The company has a history of operating losses and is reliant on external financing.
• There is no guarantee of FDA approval for the AVERSA Fentanyl product.
• The company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (Gunnar) and Lucosky Brookman LLP (LB) in the Supreme Court of the State of New York.

Risks

• The FDA regulatory process may take longer and be more expensive than anticipated.
• There is no assurance of obtaining FDA approval for the AVERSA Fentanyl product.
• The company may not be able to launch any products for which it receives FDA marketing approval.
• Establishing a distribution network and manufacturing facilities may be challenging.
• The company may need to enter into a joint venture or strategic relationship, which may not be successful.
• Accurately estimating expenses, capital requirements, and financing needs may be difficult.
• The company may face competition from better-known and better-capitalized companies.
• The company
• s stock price has been volatile and may continue to be so.','The company is currently a defendant in a lawsuit that could result in substantial costs and a diversion of management's attention and resources.'

Future Outlook

The company expects to continue incurring substantial expenses as it continues with product development and clinical trials for its AVERSA Fentanyl product. The timing of potential FDA product approval may be delayed if additional studies are required. The company anticipates that it will need approximately $13 million for research and development of its abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical trials that need to be completed to obtain FDA approval, but the total cost could be substantially in excess of that amount.

Management Comments

• Management believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements.
• Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the recent equity financing and credit facility.

Industry Context

Nutriband's focus on developing an abuse-deterrent fentanyl transdermal system aligns with the broader industry trend of addressing the opioid crisis. The company's technology could provide a safer alternative to existing opioid products, potentially reducing the risk of abuse and misuse.

Comparison to Industry Standards

• Compared to industry standards, Nutriband
• s abuse-deterrent technology is novel. For example, Purdue Pharma's OxyContin, an oral opioid, has faced criticism for its role in the opioid crisis, while Nutriband's transdermal patch aims to deter abuse.','Insys Therapeutics, another player in the opioid market, faced legal challenges related to its marketing practices. Nutriband's focus on abuse deterrence differentiates it from such companies.','Compared to companies like Durect Corporation, which develops abuse-deterrent pain medications, Nutriband's transdermal approach is unique. Durect's ORADUR technology is for oral medications, while Nutriband focuses on a patch delivery system.','Egalet, another competitor in the abuse-deterrent space, was acquired by Assertio Therapeutics. Egalet's products, like SPRIX Nasal Spray, used different delivery mechanisms than Nutriband's transdermal system.'

Corporate Governance

Legal Proceedings

• The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (Gunnar) and Lucosky Brookman LLP (LB) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Companys termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees. In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims. Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.

Related Party Transactions

• In March 2024, options to purchase 390,000 shares of common stock were issued to executives and employees of the Company at a price of $2.37 and $2.61 per share.
• On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors, which included related parties. The related parties invested a total of $7,120,000 and received 1,780,000 shares of common stock and warrants to purchase 3,560,000 shares of common stock @ $6.43 per share.
• During the three months ended April 30, 2024, the Company received $300,000 from the credit line facility with TII Jet Services LDA.
• On February 1, 2023, options to purchase 30,000 shares of the Companys common stock were issued to an executive of the Company at a price of $3.975 per share.

Stakeholder Impact

• Shareholders: Potential dilution from equity financing and stock option exercises; stock price volatility.
• Employees: Potential benefits from stock options; job security tied to company
• s financial performance.','Customers: Potential access to a new abuse-deterrent fentanyl product if approved.','Suppliers: Continued business from contract manufacturing operations.','Creditors: Increased financial stability due to recent equity financing.'

Next Steps

• Continue with product development and clinical trials for the AVERSA Fentanyl product.
• Seek FDA approval for the AVERSA Fentanyl product.
• Potentially establish a distribution network for the marketing and sale of products upon FDA approval.
• Explore potential joint ventures or strategic relationships for product development, manufacturing, or marketing.
• Submit the Amendment to the 2021 Employees Stock Option Plan to stockholders for adoption and approval at the 2025 Annual Meeting.

Key Dates

Keywords

transdermal, pharmaceutical, fentanyl, abuse deterrent, FDA approval, clinical trials, contract manufacturing, research and development, opioid, healthcare, drug delivery, AVERSA, Pocono Coated Products, Active Intelligence, 4P Therapeutics